Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group; Rossing P, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102:S1–S127. doi: 10.1016/j.kint.2022.06.008
de Boer IH, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45:3075–3090. doi: 10.2337/dci22-0027
Brosius FC, et al.; DKD-Collaborative ASN Taskforce. Transforming the care of patients with diabetic kidney Disease. Clin J Am Soc Nephrol 2021; 16:1590–1600. doi: 10.2215/CJN.18641120
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Diabetic kidney disease. Accessed January 3, 2022. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease
Zelnick LR, et al. Diabetes and CKD in the United States population, 2009–2014. Clin J Am Soc Nephrol 2017; 12:1984–1990. doi: 10.2215/CJN.03700417
Shepherd J; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2:1131–1139. doi: 10.2215/CJN.04371206
Shaffer R, Parker MG. How the changing health care environment will exacerbate the nephrology workforce crisis. Kidney News, May 2011; 3(5):10–11. https://www.asn-online.org/publications/kidneynews/archives/2011/KN_2011_05_may.pdf
Vu A, et al. “Positive kidney health”: Implementation and design of a pharmacist-led intervention for patients at risk for development or progression of chronic kidney disease. J Am Pharm Assoc (2003) (published online ahead of print November 17, 2022). doi: 10.1016/j.japh.2022.11.007; https://www.japha.org/article/S1544-3191(22)00387-9/fulltext